Doxorubicin-related cardiotoxicity: review of fundamental pathways of cardiovascular system injury

Over the years, advancements in the field of oncology have made remarkable strides in enhancing the efficacy of medical care for patients with cancer. These modernizations have resulted in prolonged survival and improved the quality of life for these patients. However, this progress has also been accompanied by escalation in mortality rates associated with anthracycline chemotherapy. Anthracyclines, which are known for their potent antitumor properties, are notorious for their substantial cardiotoxic potential. Remarkably, even after 6 decades of research, a conclusive solution to protect the cardiovascular system against doxorubicin-induced damage has not yet been established. A comprehensive understanding of the pathophysiological processes driving cardiotoxicity combined with targeted research is crucial for developing innovative cardioprotective strategies. This review seeks to explain the mechanisms responsible for structural and functional alterations in doxorubicin-induced cardiomyopathy. © 2024

Авторы
Avagimyan A. , Pogosova N. , Kakturskiy L. , Sheibani M. , Challa A. , Kogan E. , Fogacci F. , Mikhaleva L. , Vandysheva R. , Yakubovskaya M. , Faggiano A. , Carugo S. , Urazova O. , Jahanbin B. , Lesovaya E. , Polana S. , Kirsanov K. , Sattar Y. , Trofimenko A. , Demura T. , Saghazadeh A. , Koliakos G. , Shafie D. , Alizadehasl A. , Cicero A. , Costabel J.P. , Biondi-Zoccai G. , Ottaviani G. , Sarrafzadegan N.
Журнал
Cardiovascular Pathology
Издательство
Elsevier Inc.
Язык
Английский
Статус
Опубликовано
Ссылка
Внешняя ссылка
DOI
10.1016/J.CARPATH.2024.107683
Номер
107683
Том
73
Год
2024
Организации
  • 1 Department of Internal Desiases Propedeutics, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia
  • 2 Deputy Director of Research and Preventive Cardiology, National Medical Research Centre of Cardiology named after E. Chazov, Moscow, Russian Federation
  • 3 Head of Evidence Based Medicine Department, Patrice Lumumba Peoples' Friendship University of Russia (RUDN), Moscow, Russian Federation
  • 4 A. P. Avtsyn Research Institute of Human Morphology, Petrovskiy RNCS, Moscow, Russian Federation
  • 5 Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Teharan, Iran
  • 6 Razi Drug Research Centre, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  • 7 Department of Cardiology, West Virginia University, Morgantown, WV, United States
  • 8 Institute of Clinical Morphology and Digital Pathology, I. M. Sechenov First Moscow State Medical University, Moscow, Russian Federation
  • 9 Atherosclerosis and Metabolic Disorders Research Unit, Alma Mater Studiorum University of Bologna, Bologna, Italy
  • 10 Chemical Cancerogenesis Department, Institute of Cancerogenesis, National Medical Research Center of Oncology after N. N. Blokhina, Moscow, Russian Federation
  • 11 Laboratory of Single Cell Biology, Patrice Lumumba Peoples' Friendship University of Russia (RUDN), Moscow, Russian Federation
  • 12 Department of Cardio-Thoracic-Vascular Area, Foundation IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy
  • 13 Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
  • 14 Head of Pathophysiology Department, Siberian State Medical University, Tomsk, Russian Federation
  • 15 Department of Pathology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
  • 16 Department of Oncology, Ryazan State Medical University after I. P. Pavlov, Ryazan, Russian Federation
  • 17 Jawaharlal Nehru Medical College, Belgaum, India
  • 18 Department of Pathophysiology, Kuban State Medical University, Krasnodar, Russian Federation
  • 19 Head of Laboratory of Biological Chemistry, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
  • 20 Director of Heart Failure Centre, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
  • 21 Head of Cardio-Oncology Department and Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
  • 22 Hypertension and Cardiovascular Risk Research Unit, Alma Mater Studiorum University of Bologna, Bologna, Italy
  • 23 IRCCS Policlinico S. Orsola-Malpighi di Bologna, Bologna, Italy
  • 24 Chief of Coronary Care Unit, Buenos Aires Institute of Cardiology, Buenos Aires, Argentina
  • 25 Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy
  • 26 Maria Cecilia Hospital, GVM Care and Research, Cotignola, Italy
  • 27 Anatomic Pathology, Lino Rossi Research Center, Department of Biomedical, Surgical and Dental Sciences, Università degli Studi di Milano, Milan, Italy
  • 28 Director of Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
  • 29 School of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, Canada
Ключевые слова
Cardio-oncology; Cardiotoxicity; Chemotherapy; Doxorubicin
Цитировать
ГОСТ MLA RIS BibTex
Поделиться

Другие записи